Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25691251)

  • 1. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
    Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
    Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
    Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
    BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
    Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
    PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
    Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
    Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
    Wu L; Zhang J; Wu H; Han E
    Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
    Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
    Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer.
    Sato T; Oshima T; Yoshihara K; Yamamoto N; Yamada R; Nagano Y; Fujii S; Kunisaki C; Shiozawa M; Akaike M; Rino Y; Tanaka K; Masuda M; Imada T
    Oncol Rep; 2009 Jan; 21(1):211-6. PubMed ID: 19082464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.
    Chin CC; Li JM; Lee KF; Huang YC; Wang KC; Lai HC; Cheng CC; Kuo YH; Shi CS
    J Cell Physiol; 2016 Feb; 231(2):459-72. PubMed ID: 26189563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
    Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
    Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
    Jin ZZ; Wang W; Fang DL; Jin YJ
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for
    Yang Z; Liang SQ; Yang H; Xu D; Bruggmann R; Gao Y; Deng H; Berezowska S; Hall SRR; Marti TM; Kocher GJ; Zhou Q; Schmid RA; Peng RW
    Cancer Res; 2021 Jun; 81(11):3121-3133. PubMed ID: 33685992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.